For traditional chemotherapies, BRAF inhibitors such as vemurafenib (PLX4032) and encorafenib, or MEK inhibitors such as cobimetinib, trametinib, and binimeinib, have been used for the treatment of melanomas mainly by inhibiting cell proliferation by blocking downstream ERK1/2 activity40–42. Here, MAP2K7 is linked to melanoma.